Does Rallies show 13F holders for QURE?

Yes. Rallies tracks hedge fund and 13F ownership data for QURE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is QURE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for QURE. It does not provide personalized investment advice.

QURE (uniQure N.V.) Stock Analysis - Hedge Fund Holdings

uniQure N.V. (QURE) is a publicly traded Healthcare sector company. As of May 21, 2026, QURE trades at $24.60 with a market cap of $1.57B and a P/E ratio of -7.01. QURE moved -0.45% today. Year to date, QURE is +8.71%; over the trailing twelve months it is +60.68%. Its 52-week range spans $4.45 to $71.50. Analyst consensus is buy with an average price target of $38.80. Rallies surfaces QURE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns QURE stock?

Hedge funds tracked by Rallies that own QURE include Orbimed Advisors, Maverick Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for uniQure N.V..

QURE Key Metrics

Key financial metrics for QURE
Metric	Value
Price	$24.60
Market Cap	$1.57B
P/E Ratio	-7.01
EPS	$-3.48
Dividend Yield	0.00%
52-Week High	$71.50
52-Week Low	$4.45
Volume	0
Avg Volume	0
Revenue (TTM)	$18.09M
Net Income	$-208.87M
Gross Margin	90.56%

Top Hedge Funds Holding QURE

Orbimed Advisors holds 2.14M shares of QURE, changed +189.69% as of Mar 31, 2026.
Maverick Capital holds 697.64K shares of QURE, changed +5.41% as of Mar 31, 2026.
Farallon Capital holds 14.00K shares of QURE, changed +0.00% as of Mar 31, 2026.

Latest QURE News

uniQure to File Q3 2026 AMT-130 UK MAA After 75% Huntington’s Slowing — Apr 30, 2026
uniQure Shares Rally as CBER Head Departs, AMT-130 Review Path May Open — Mar 9, 2026
uniQure Stock Soars 36% After FDA CBER Chief Resignation — Mar 9, 2026
uniQure Shares Surge Over 30% as FDA Biologics Chief Exits — Mar 9, 2026
UniQure Shares Surge 70% after FDA Division Chief Departure — Mar 7, 2026

Recent QURE Insider Trades

Abi-Saab Walid sold 25.00K (~$627.50K) on May 8, 2026.
Abi-Saab Walid sold 20.00K (~$500.00K) on May 8, 2026.
Kapusta Matthew C sold 14.58K (~$132.10K) on Mar 4, 2026.

QURE Analyst Consensus

12 analysts cover QURE: 0 strong buy, 8 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $38.80.

Common questions about QURE

Who owns QURE stock?: Hedge funds tracked by Rallies that own QURE include Orbimed Advisors, Maverick Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for uniQure N.V..
Does Rallies show 13F holders for QURE?: Yes. Rallies tracks hedge fund and 13F ownership data for QURE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is QURE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for QURE. It does not provide personalized investment advice.